PFE stock news · Pfizer
Get alerts for PFE
Follow Pfizer (PFE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PFEPfizer is testing a new online system to speed up how it delivers medicines.
Good for PFEPfizer is testing a cloud-based lab system meant to speed medicine delivery and support AI research. The plan may improve operations, but results are not yet shown.
Roche has stopped future investments in Germany because of a disagreement about drug price cuts.
NeutralPfizer has put its German spending plans under review, but the story reports no cut or other change to its business. Its outlook is unchanged by this report.
JD Vance praises TrumpRx for lowering drug prices, calling it a win for American jobs before the midterms.
NeutralTrumpRx aims to lower prescription prices, and Pfizer is named in contracts with hidden terms. No price change or financial result is given, so the story does not show a change to Pfizer's outlook.
Pfizer's stock just reached its highest point in a year. What’s happening?
Good for PFEPfizer received FDA approval for a breast cancer treatment plan, and trial patients went longer before their disease worsened. This favors Pfizer, though drugmakers rose broadly and the approval was reported earlier.
Stephen King criticizes Trump’s new press secretary for her old posts about vaccines and election claims.
NeutralThe story mentions Pfizer’s recent share rise but reports no new company development or link between the dispute and Pfizer’s business.
The drug industry is suing the Trump administration, saying the new Medicare drug pricing rule is illegal and unfair.
NeutralPfizer has a White House pricing deal, and CMS plans to exempt such firms from a rule expected to reach few drugs. PhRMA’s suit seeks to block it, but the savings estimate fell to $440 million over 7 years from $11.9 billion, leaving Pfizer’s outlook little changed.
Pfizer gets FDA approval to use its breast cancer drug for more patients with advanced disease.
Good for PFEPfizer won FDA approval to use TUKYSA earlier for advanced breast cancer. Trial results support a positive reading, despite a separate vaccine lawsuit mentioned in the article.
Florida's Attorney General is taking Pfizer to court for making false claims about the safety of its COVID-19 vaccine.
Bad for PFEFlorida has sued Pfizer over alleged vaccine safety and spread claims. The suit raises legal and trust concerns despite more than $80 billion in past vaccine sales.
Pfizer says its eczema medicine helps clear up skin a lot.
Good for PFEPfizer reported encouraging Phase 2 results for its eczema drug across several doses. The findings support the drug's prospects, though it has not been approved.
Invivyd is moving quickly to ask the FDA to approve its COVID-19 antibody.
NeutralThe report compares Pfizer’s vaccine alone with Invivyd’s antibody and the combined treatment. The combination showed fewer short-term side effects and higher antibody levels, but the story reports no new agreement or change in Pfizer’s sales.
Invivyd is getting ready to ask the FDA to quickly approve its COVID-19 antibody treatment.
NeutralPfizer's Comirnaty vaccine was tested alone and with Invivyd's candidate. The report gives no news about a change to Pfizer's own business outlook.
Big trades in 10 health care stocks happened today.
NeutralPfizer had a put trade labeled bearish. This reports trader activity, not a change in Pfizer's business, so it does not change its outlook.
Pete Buttigieg calls out corruption in U.S. politics, saying big companies are taking over elections and getting what they want.
NeutralPfizer was lumped into a political critique of 'Big Pharma'; the broad comment adds no new policy and does not change Pfizer's outlook.
Merck is one step closer to getting approval in Europe for its Keytruda treatment for bladder cancer.
Good for PFEPfizer was a partner on the Phase 3 KEYNOTE-B15 study that underpins the recommendation, supporting Pfizer's role in the combination's commercial opportunity; the European Commission will decide by Q4 2026.
Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.
Bad for PFEPfizer is listed among firms previously subject to the administration's pricing agreements, indicating vulnerability to reduced U.S. drug prices.
Pfizer's aspirations in cancer vaccines face heightened competition following Merck's expanded partnership with Moderna.
Bad for PFEPfizer's cancer vaccine ambitions are challenged by Merck's aggressive strategy, which may hinder its competitive position in the market.
Wednesday sees an uptick in Pfizer shares amid positive investor sentiment.
Good for PFEPfizer's stock is rising as investors react positively to the successful trial results of Merck and Moderna's mRNA cancer therapy, which validates the mRNA technology that Pfizer is also involved with through its partnership with BioNTech. This development positions Pfizer favorably in the mRNA market, leading to increased investor optimism.
Pfizer and Valneva's application for a Lyme disease vaccine receives validation from European regulators.
NeutralThe European Medicines Agency has validated the Marketing Authorization Application for Pfizer and Valneva's Lyme disease vaccine, which is a crucial step towards potential approval and commercialization. This news has led to a significant increase in Valneva's stock price and is expected to positively impact Pfizer as well.